Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envarsus XR in Delayed Graft Function
NCT03864926Phase 4Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Mar 2019
- Primary completion
- Jul 2022
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in delayed graft function (DGF) and kidney transplant rejection comparing Envarsus XR with Standard of Care (2 arms). Primary endpoint: Number of Days Needed to Recover From Delayed Graft Function. Started Mar 2019; status: completed.
02
Drugs
tacrolimus
03
Conditions
delayed graft function (DGF)kidney transplant rejection
Beyond the preview
Go deeper on NCT03864926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03864926.